SV Health Investors, LLC - Q2 2018 holdings

$218 Million is the total value of SV Health Investors, LLC's 8 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 42.9% .

 Value Shares↓ Weighting
AVRO NewAVROBIO INC$78,141,0002,736,027
+100.0%
35.88%
DCPH  DECIPHERA PHARMACEUTICALS INC$67,537,000
+96.4%
1,716,3030.0%31.01%
+20.2%
TRXC  TRANSENTERIX INC$32,903,000
+156.5%
7,546,6920.0%15.11%
+57.0%
KALV  KALVISTA PHARMACEUTICALS INC$20,945,000
-14.3%
2,579,4900.0%9.62%
-47.6%
OCUL SellOCULAR THERAPEUTIX INC$8,406,000
-19.6%
1,245,270
-22.4%
3.86%
-50.8%
ASNS  ARSANIS INC$6,785,000
-84.1%
1,868,9610.0%3.12%
-90.3%
CATB  CATABASIS PHARMACEUTICALS IN$2,740,000
-47.0%
2,857,6670.0%1.26%
-67.6%
ETRM NewRESHAPE LIFE SCIENCES INC$346,000150,064
+100.0%
0.16%
RSLS ExitRESHAPE LIFE SCIENCES INC$0-2,250,958
-100.0%
-2.45%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • SVLSF IV, LLC #1
  • SV Life Sciences Fund IV (GP), L.P. #2
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-08-06
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
TRANSENTERIX, INC.27Q4 202024.0%
OCULAR THERAPEUTIX, INC.24Q2 202035.9%
KALVISTA PHARMACEUTICALS INC17Q4 202031.0%
DECIPHERA PHARMACEUTICALS INC17Q3 202131.0%
CATABASIS PHARMACEUTICALS, INC.15Q4 201818.2%
X4 PHARMACEUTICALS INC15Q3 20223.2%
BICYCLE THERAPEUTICS PLC14Q3 202265.4%
SUTRO BIOPHARMA INC14Q4 202119.1%
ENTELLUS MED INC12Q4 201764.4%
AVROBIO INC12Q1 202141.6%

View SV Health Investors, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2022-11-07
13F-HR2022-08-12
13F-HR2022-05-16
13F-HR2022-02-11
13F-HR2021-11-15
13F-HR2021-08-16
13F-HR2021-05-17
13F-HR2021-02-16
13F-HR2020-11-12
13F-HR2020-08-14

View SV Health Investors, LLC's complete filings history.

Compare quarters

Export SV Health Investors, LLC's holdings